Mitabor Disper (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonising postsynaptic 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic activity. Histamine H1 receptor blockade also contributes to its sedative and appetite‑stimulating effects.

The appropriate dose of Mitabor Disper is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Physicians typically start with a low dose and may adjust it as needed; exact dosing regimens are not provided here.

Safety data for mirtazapine during pregnancy and lactation are limited. Prescribers must weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing women.

To order Mitabor Disper, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct receptor profile that often results in stronger sedative and appetite‑stimulating effects, making it useful for patients with insomnia or weight loss. It may be chosen when SSRIs are ineffective or poorly tolerated.

Store Mitabor Disper at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Mitabor Disper is taken orally as a tablet. Patients should swallow the tablet whole with water, preferably in the evening due to its sedative effect, unless otherwise directed by the prescriber.

Serious risks include agranulocytosis, severe neutropenia, suicidal thoughts or behaviors, hepatic dysfunction, severe hypersensitivity reactions, and seizures. Patients should seek immediate medical attention if they experience signs of infection, jaundice, severe rash, or new psychiatric symptoms.

Mitabor Disper should be avoided in individuals with known hypersensitivity to mirtazapine, those currently taking monoamine oxidase inhibitors, patients with severe hepatic impairment, and anyone for whom the risk–benefit profile is unfavorable as determined by a qualified healthcare professional.